Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking

M. Yang, S. Safavi, EL. Woodward, N. Duployez, L. Olsson-Arvidsson, J. Ungerbäck, M. Sigvardsson, M. Zaliova, J. Zuna, T. Fioretos, B. Johansson, KH. Nord, K. Paulsson

. 2020 ; 136 (8) : 946-956. [pub] 20200820

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21012250

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene in 13q12.2 are among the most common driver events in acute leukemia, leading to increased cell proliferation and survival through activation of the phosphatidylinositol 3-kinase/AKT-, RAS/MAPK-, and STAT5-signaling pathways. In this study, we examine the pathogenetic impact of somatic hemizygous 13q12.2 microdeletions in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) using 5 different patient cohorts (in total including 1418 cases). The 13q12.2 deletions occur immediately 5' of FLT3 and involve the PAN3 locus. By detailed analysis of the 13q12.2 segment, we show that the deletions lead to loss of a topologically associating domain border and an enhancer of FLT3. This results in increased cis interactions between the FLT3 promoter and another enhancer located distally to the deletion breakpoints, with subsequent allele-specific upregulation of FLT3 expression, expected to lead to ligand-independent activation of the receptor and downstream signaling. The 13q12.2 deletions are highly enriched in the high-hyperdiploid BCP ALL subtype (frequency 3.9% vs 0.5% in other BCP ALL) and in cases that subsequently relapsed. Taken together, our study describes a novel mechanism of FLT3 involvement in leukemogenesis by upregulation via chromatin remodeling and enhancer hijacking. These data further emphasize the role of FLT3 as a driver gene in BCP ALL.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012250
003      
CZ-PrNML
005      
20210507101735.0
007      
ta
008      
210420s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood.2019004684 $2 doi
035    __
$a (PubMed)32384149
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Yang, Minjun $u Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden
245    10
$a 13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking / $c M. Yang, S. Safavi, EL. Woodward, N. Duployez, L. Olsson-Arvidsson, J. Ungerbäck, M. Sigvardsson, M. Zaliova, J. Zuna, T. Fioretos, B. Johansson, KH. Nord, K. Paulsson
520    9_
$a Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene in 13q12.2 are among the most common driver events in acute leukemia, leading to increased cell proliferation and survival through activation of the phosphatidylinositol 3-kinase/AKT-, RAS/MAPK-, and STAT5-signaling pathways. In this study, we examine the pathogenetic impact of somatic hemizygous 13q12.2 microdeletions in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) using 5 different patient cohorts (in total including 1418 cases). The 13q12.2 deletions occur immediately 5' of FLT3 and involve the PAN3 locus. By detailed analysis of the 13q12.2 segment, we show that the deletions lead to loss of a topologically associating domain border and an enhancer of FLT3. This results in increased cis interactions between the FLT3 promoter and another enhancer located distally to the deletion breakpoints, with subsequent allele-specific upregulation of FLT3 expression, expected to lead to ligand-independent activation of the receptor and downstream signaling. The 13q12.2 deletions are highly enriched in the high-hyperdiploid BCP ALL subtype (frequency 3.9% vs 0.5% in other BCP ALL) and in cases that subsequently relapsed. Taken together, our study describes a novel mechanism of FLT3 involvement in leukemogenesis by upregulation via chromatin remodeling and enhancer hijacking. These data further emphasize the role of FLT3 as a driver gene in BCP ALL.
650    _2
$a buněčné linie $7 D002460
650    _2
$a restrukturace chromatinu $x genetika $x fyziologie $7 D042002
650    _2
$a chromozomální delece $7 D002872
650    _2
$a chromozomální poruchy $x komplikace $x genetika $7 D025063
650    _2
$a lidské chromozomy, pár 13 $x genetika $7 D002882
650    _2
$a kohortové studie $7 D015331
650    _2
$a variabilita počtu kopií segmentů DNA $x genetika $7 D056915
650    _2
$a zesilovače transkripce $x genetika $7 D004742
650    _2
$a regulace genové exprese u leukemie $7 D015973
650    _2
$a lidé $7 D006801
650    _2
$a mikročipová analýza $7 D046228
650    _2
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a akutní lymfatická leukemie $x genetika $7 D054198
650    _2
$a sekvenování transkriptomu $7 D000081246
650    _2
$a upregulace $x genetika $7 D015854
650    _2
$a sekvenování celého genomu $7 D000073336
650    _2
$a tyrosinkinasa 3 podobná fms $x genetika $7 D051941
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Safavi, Setareh $u Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden
700    1_
$a Woodward, Eleanor L $u Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden
700    1_
$a Duployez, Nicolas $u Laboratory of Hematology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France $u Unité Mixte de Recherche en Santé (UMR_S) 1172, INSERM/University of Lille, Lille, France
700    1_
$a Olsson-Arvidsson, Linda $u Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden $u Division of Laboratory Medicine, Department of Clinical Genetics and Pathology, Skåne University Hospital, Lund, Sweden
700    1_
$a Ungerbäck, Jonas $u Division of Molecular Hematology, Lund Stem Cell Center, Department of Laboratory Medicine, Lund University, Lund, Sweden
700    1_
$a Sigvardsson, Mikael $u Division of Molecular Hematology, Lund Stem Cell Center, Department of Laboratory Medicine, Lund University, Lund, Sweden $u Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
700    1_
$a Zaliova, Marketa $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University/University Hospital Motol, Prague, Czech Republic; and $u Childhood Leukaemia Investigation Prague (CLIP), Prague, Czech Republic
700    1_
$a Zuna, Jan $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University/University Hospital Motol, Prague, Czech Republic; and $u Childhood Leukaemia Investigation Prague (CLIP), Prague, Czech Republic
700    1_
$a Fioretos, Thoas $u Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden $u Division of Laboratory Medicine, Department of Clinical Genetics and Pathology, Skåne University Hospital, Lund, Sweden
700    1_
$a Johansson, Bertil $u Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden $u Division of Laboratory Medicine, Department of Clinical Genetics and Pathology, Skåne University Hospital, Lund, Sweden
700    1_
$a Nord, Karolin H $u Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden
700    1_
$a Paulsson, Kajsa $u Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 136, č. 8 (2020), s. 946-956
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32384149 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507101735 $b ABA008
999    __
$a ok $b bmc $g 1650589 $s 1132629
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 136 $c 8 $d 946-956 $e 20200820 $i 1528-0020 $m Blood $n Blood $x MED00000807
LZP    __
$a Pubmed-20210420

Find record

Citation metrics

Archiving options